January 17, 2024 07:15 AM ESTUpdated 11:15 AM
R&D
Cell/Gene Tx

Re­genxbio touts pos­i­tive mid-stage da­ta for Ab­b­Vie-part­nered vi­sion-loss gene ther­a­py, but no de­tailed plans for piv­otal study

Katherine Lewin

News Reporter

Re­genxbio re­leased pos­i­tive in­ter­im da­ta from its Phase II tri­al of its Ab­b­Vie-part­nered vi­sion-loss gene ther­a­py pro­gram, tout­ing “sta­ble” vi­su­al acu­ity …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times